Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26,901 Mln
P/E Ratio
48.31
P/B Ratio
12.79
Industry P/E
--
Debt to Equity
1.2
ROE
0.28 %
ROCE
12.4 %
Div. Yield
0 %
Book Value
5.17
EPS
1.42
CFO
$2,994.60 Mln
EBITDA
$1,895.00 Mln
Net Profit
$1,309.20 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
DexCom (DXCM)
| -14.99 | -11.98 | -21.65 | -49.42 | -18.93 | -3.94 | 14.48 |
|
BSE Sensex*
| 1.77 | 3.54 | 5.00 | 8.95 | 11.20 | 21.05 | 11.15 |
|
S&P Midcap 400
| -13.99 | -9.45 | -17.25 | -5.50 | -0.27 | 11.83 | 5.78 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
DexCom (DXCM)
| -37.09 | 9.58 | -15.64 | 45.23 | 69.02 | 82.59 | 107.91 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 196.61 | 57,056.60 | 33.45 | 6.76 | |
| 69.20 | 41,899.05 | 30.57 | 50.15 | |
| 406.65 | 33,354.44 | 38.61 | 57.66 | |
| 210.08 | 35,134.20 | 49.99 | 13.63 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes... and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Address: 6340 Sequence Drive, San Diego, CA, United States, 92121 Read more
Executive Chairman, CEO & President
Mr. Kevin Ronald Sayer
Executive Chairman, CEO & President
Mr. Kevin Ronald Sayer
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of DexCom Inc (DXCM) stood at $ 6,485 Mln as on 31-Dec-24
The share price of DexCom Inc (DXCM) is $66.11 (NASDAQ) as of 21-Apr-2025 16:00 EDT. DexCom Inc (DXCM) has given a return of -18.93% in the last 3 years.
DexCom Inc (DXCM) has a market capitalisation of $ 26,901 Mln as on 21-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/E ratio of DexCom Inc (DXCM) is 48.31 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the DexCom Inc (DXCM) and enter the required number of quantities and click on buy to purchase the shares of DexCom Inc (DXCM).
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Address: 6340 Sequence Drive, San Diego, CA, United States, 92121
The CEO & director of Mr. Kevin Ronald Sayer. is DexCom Inc (DXCM), and CFO & Sr. VP is Mr. Kevin Ronald Sayer.
There is no promoter pledging in DexCom Inc (DXCM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
5,754
|
|
|
4,171
|
|
|
3,590
|
|
|
3,274
|
| DexCom Inc. (DXCM) | Ratios |
|---|---|
|
Return on equity(%)
|
27.63
|
|
Operating margin(%)
|
15.45
|
|
Net Margin(%)
|
14.29
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of DexCom Inc (DXCM) was $576 Mln.
$-2.46
(
